LivaNova PLC
LIVN55.000USD
-0.910-1.63%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
3.00BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über LivaNova PLC Unternehmen
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Unternehmensinformationen
BörsenkürzelLIVN
Name des UnternehmensLivaNova PLC
IPO-datumOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Anzahl der mitarbeiter2900
WertpapierartOrdinary Share
GeschäftsjahresendeOct 19
Addresse20 Eastbourne Terrace
StadtLONDON
BörseNASDAQ Global Select Consolidated
LandUnited Kingdom
PostleitzahlW2 6LG
Telefon442033250662
Websitehttps://www.livanova.com/
BörsenkürzelLIVN
IPO-datumOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
32.57K
+15.05%
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
26.68K
--
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
12.75K
--
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
+19.06%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
9.06K
+49.63%
Mr. Francesco Bianchi
Mr. Francesco Bianchi
Independent Director
Independent Director
9.03K
-14.25%
Franco Poletti ,
Franco Poletti ,
President, Cardiopulmonary Business Unit
President, Cardiopulmonary Business Unit
8.52K
+4.49%
Ms. Brooke Story
Ms. Brooke Story
Independent Director
Independent Director
6.48K
+86.48%
Mr. Michael Damon Hutchinson
Mr. Michael Damon Hutchinson
Senior Vice President, Chief Legal Officer, Company Secretary
Senior Vice President, Chief Legal Officer, Company Secretary
5.67K
--
Ahmet Tezel
Ahmet Tezel
Senior Vice President, Chief Innovation Officer
Senior Vice President, Chief Innovation Officer
1.94K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
32.57K
+15.05%
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
26.68K
--
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
12.75K
--
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
+19.06%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
9.06K
+49.63%
Mr. Francesco Bianchi
Mr. Francesco Bianchi
Independent Director
Independent Director
9.03K
-14.25%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
169.16M
53.39%
Rest of World
87.99M
27.77%
Europe
59.70M
18.84%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.67%
PRIMECAP Management Company
8.50%
The Vanguard Group, Inc.
4.47%
Millennium Management LLC
4.44%
State Street Global Advisors (US)
3.81%
Andere
67.10%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.67%
PRIMECAP Management Company
8.50%
The Vanguard Group, Inc.
4.47%
Millennium Management LLC
4.44%
State Street Global Advisors (US)
3.81%
Andere
67.10%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
47.32%
Investment Advisor/Hedge Fund
34.23%
Hedge Fund
15.48%
Research Firm
3.07%
Pension Fund
2.18%
Bank and Trust
1.36%
Individual Investor
0.38%
Sovereign Wealth Fund
0.12%
Insurance Company
0.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
564
56.85M
104.11%
-6.95M
2025Q1
581
56.61M
103.82%
-8.04M
2024Q4
586
56.98M
104.84%
-8.56M
2024Q3
563
55.15M
101.56%
-9.48M
2024Q2
546
57.21M
105.64%
-8.52M
2024Q1
547
58.00M
107.51%
-6.90M
2023Q4
532
56.62M
105.11%
-7.28M
2023Q3
527
56.14M
104.20%
-8.51M
2023Q2
529
55.56M
103.33%
-9.55M
2023Q1
544
57.05M
106.52%
-4.67M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
6.53M
11.97%
-36.05K
-0.55%
Mar 31, 2025
PRIMECAP Management Company
4.61M
8.45%
-145.65K
-3.06%
Mar 31, 2025
The Vanguard Group, Inc.
2.65M
4.87%
+316.99K
+13.56%
Mar 31, 2025
Millennium Management LLC
2.07M
3.79%
-983.66K
-32.27%
Mar 31, 2025
State Street Global Advisors (US)
2.10M
3.85%
-950.00
-0.05%
Mar 31, 2025
AQR Capital Management, LLC
1.57M
2.88%
+829.12K
+111.71%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.33M
2.44%
+20.96K
+1.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.41M
2.59%
+73.94K
+5.53%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
